Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development

Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets.

  • Rznomics partners with Lilly Gateway Labs to speed up RNA therapeutic development
  • Collaboration focuses on expanding target gene database and global clinical infrastructure
  • CEO Seong-Wook Lee sees partnership as major step for RNA platform

More from Monday 24 August →